Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China

Aims To explore the quality of life (QOL) in patients with myasthenia gravis (MG) and factors associated with QOL. Methods This observational study included patients with MG diagnosed at the First Affiliated Hospital of Fujian Medical University between January 2020 and March 2022. The QOL of patients was evaluated with the 15-item Myasthenia Gravis Quality of Life (MG-QOL15). Current MG severity was evaluated with MGFA grade, MG-ADL score, MGC score, and MGFA Postintervention Status. The data about gender, age of onset, subgroup, antibodies, age, duration, education, employment state, marital status, skeletal muscle affected, thymic histology, and current treatment methods of the patient were collected. Results A total of 185 patients [72 males (38.9%), aged 45.2 years (14–77)] with MG were enrolled. Age at onset was 38.3 ± 17.9 years, and disease duration was 87.9 months (0–672). The median MG-QOL15 score was 12.5 (0–58). The item “have trouble using my eyes” was the highest scoring item in both ocular and generalized patients with MG. The MG-QOL15 score was significantly different among patients with OMG (9.2 ± 9.4, n = 63), GMG (9.0 ± 8.8, n = 22), and BMG (15.4 ± 14.2, n = 100) (P = 0.018). Patients with BMG had higher MG-QOL15 scores than OMG (P = 0.001) and GMG (P = 0.009), but there was no significant difference between OMG and GMG (P = 0.467). The MG-QOL15 score was significantly lower in patients who had undergone thymectomy (9.7 ± 9.8, n = 58) compared to those who had not (13.8 ± 13.4, n = 127, P = 0.022). MG-QOL15 score was significantly lower in patients who underwent thymectomy compared to those who did not (9.7 ± 9.8, n = 58 vs. 13.8 ± 13.4, n = 127, P = 0.022). MG-QOL15 score was different among MGFA grades (Remission: 5.2 ± 5.4, n = 41; I: 11.3 ± 10, n = 61; II: 11.6 ± 11.1, n = 40; III: 18.1 ± 12.1, n = 29; and IVa: 30.1 ± 20, n = 14, P < 0.001). There was no significant difference between patients in MGFA grade I and II (P = 0.896), and there was no significant difference between patients in MGFA grade III and IVa (P = 0.052). MG-ADL (P < 0.001) and MGC (P < 0.001) were positively correlated with MG-QOL15. Men had higher MG-QOL15 than women (P = 0.094), and LOMG had higher MG-QOL15 than EOMG (P = 0.072). Multivariate linear regression identified that higher MG-ADL (P < 0.001), higher MGC (P = 0.02), and poor employment status (P = 0.045) were independently associated with higher MG-QOL15. Conclusion Having trouble using the eyes accounted for the highest score in MG-QOL15, eye symptoms affect QOL more than limb weakness in MG. Daily life activity, disease severity, and employment status were associated with patients' QOL. Adequate treatment should be applied to improve QOL, while mild symptoms can be accepted. Men and patients over the age of 50 years of onset may need more attention.

[1]  B. Fierro,et al.  Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort , 2022, Neurology international.

[2]  J. Statland,et al.  Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial , 2021, The Lancet Neurology.

[3]  F. Shi,et al.  Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study , 2020, The Lancet regional health. Western Pacific.

[4]  F. Shi,et al.  Immunotherapy choice and maintenance for generalized myasthenia gravis in China , 2020, CNS neuroscience & therapeutics.

[5]  M. Lipowska,et al.  Determinants of Quality of Life in Myasthenia Gravis Patients , 2020, Frontiers in Neurology.

[6]  H. Kaminski,et al.  Gender differences in quality of life among patients with myasthenia gravis in China , 2020, Health and Quality of Life Outcomes.

[7]  Li Yang,et al.  Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China , 2020, Journal of Clinical Neuroscience.

[8]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[9]  M. Benatar,et al.  Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis , 2020, JAMA neurology.

[10]  J. Verschuuren,et al.  Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids , 2019, Neuromuscular Disorders.

[11]  L. Prieto-Pinto,et al.  Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature. , 2019, Intractable & rare diseases research.

[12]  P. van Damme,et al.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis , 2019, Neurology.

[13]  G. L’italien,et al.  Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life , 2019, Journal of clinical neuromuscular disease.

[14]  N. Gilhus,et al.  Myasthenia gravis , 2019, Nature Reviews Disease Primers.

[15]  M. Benatar,et al.  Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis , 2019, Muscle & nerve.

[16]  Xiuying Hu,et al.  Translation, cross‐cultural adaptation, and validation of the chinese version of the 15‐item myasthenia gravis quality of life questionnaire , 2018, Muscle & nerve.

[17]  A. Jeong,et al.  Factors associated with quality of life of people with Myasthenia Gravis , 2018, PloS one.

[18]  M. Benatar,et al.  Rituximab as treatment for anti-MuSK myasthenia gravis , 2017, Neurology.

[19]  Hidekazu Suzuki,et al.  Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study , 2017, BMJ Open.

[20]  K. Milinis Randomized Trial of Thymectomy in Myasthenia Gravis. , 2016, The New England journal of medicine.

[21]  B. C. O. Valério,et al.  Brazilian-Portuguese translation, cross-cultural adaptation and validation of the Myasthenia Gravis Composite scale. A multicentric study , 2016, Arquivos de Neuro-Psiquiatria.

[22]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[23]  A. Taly,et al.  MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India. , 2016, Neurology India.

[24]  Min Zhang,et al.  Quality of life in 188 patients with myasthenia gravis in China , 2015, The International journal of neuroscience.

[25]  J. Verschuuren,et al.  An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts , 2015, Health and Quality of Life Outcomes.

[26]  P. Mccombe,et al.  Clinical features and impact of myasthenia gravis disease in Australian patients , 2015, Journal of Clinical Neuroscience.

[27]  John H Wasson,et al.  Patient reported outcome measures in practice , 2015, BMJ : British Medical Journal.

[28]  J. Sieb Myasthenia gravis: an update for the clinician , 2014, Clinical and experimental immunology.

[29]  Jacqueline Palace,et al.  Myasthenia gravis and neuromyelitis optica spectrum disorder , 2012, Neurology.

[30]  Antonio Pflüger,et al.  Executive Summary. , 2012, Journal of the ICRU.

[31]  M. Conaway,et al.  The MG Composite , 2010, Neurology.

[32]  F. Cantor Central and Peripheral Fatigue: Exemplified by Multiple Sclerosis and Myasthenia Gravis , 2010, PM & R : the journal of injury, function, and rehabilitation.

[33]  M. Conaway,et al.  Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravis , 2008, Muscle & nerve.

[34]  H. Bard [Update for the clinician]. , 2005, Journal de radiologie.

[35]  Emily Best A rapid review of the literature , 2005 .

[36]  D B Sanders,et al.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.

[37]  R. Barohn,et al.  Myasthenia gravis , 2000, Neurology.